Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 2
2015 3
2016 2
2017 2
2018 6
2019 2
2020 4
2021 4
Text availability
Article attribute
Article type
Publication date

Search Results

22 results
Results by year
Filters applied: . Clear all
Page 1
Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition.
Mao W, Ghasemzadeh A, Freeman ZT, Obradovic A, Chaimowitz MG, Nirschl TR, McKiernan E, Yegnasubramanian S, Drake CG. Mao W, et al. Among authors: nirschl tr. J Immunother Cancer. 2019 Oct 25;7(1):277. doi: 10.1186/s40425-019-0758-y. J Immunother Cancer. 2019. PMID: 31653272 Free PMC article.
A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer target.
Freeman ZT, Nirschl TR, Hovelson DH, Johnston RJ, Engelhardt JJ, Selby MJ, Kochel CM, Lan RY, Zhai J, Ghasemzadeh A, Gupta A, Skaist AM, Wheelan SJ, Jiang H, Pearson AT, Snyder LA, Korman AJ, Tomlins SA, Yegnasubramanian S, Drake CG. Freeman ZT, et al. Among authors: nirschl tr. J Clin Invest. 2020 Mar 2;130(3):1405-1416. doi: 10.1172/JCI128672. J Clin Invest. 2020. PMID: 32015231 Free PMC article.
Elective Nodal Irradiation Attenuates the Combinatorial Efficacy of Stereotactic Radiation Therapy and Immunotherapy.
Marciscano AE, Ghasemzadeh A, Nirschl TR, Theodros D, Kochel CM, Francica BJ, Muroyama Y, Anders RA, Sharabi AB, Velarde E, Mao W, Chaudhary KR, Chaimowitz MG, Wong J, Selby MJ, Thudium KB, Korman AJ, Ulmert D, Thorek DLJ, DeWeese TL, Drake CG. Marciscano AE, et al. Among authors: nirschl tr. Clin Cancer Res. 2018 Oct 15;24(20):5058-5071. doi: 10.1158/1078-0432.CCR-17-3427. Epub 2018 Jun 13. Clin Cancer Res. 2018. PMID: 29898992 Free PMC article.
Stereotactic Radiotherapy Increases Functionally Suppressive Regulatory T Cells in the Tumor Microenvironment.
Muroyama Y, Nirschl TR, Kochel CM, Lopez-Bujanda Z, Theodros D, Mao W, Carrera-Haro MA, Ghasemzadeh A, Marciscano AE, Velarde E, Tam AJ, Thoburn CJ, Uddin M, Meeker AK, Anders RA, Pardoll DM, Drake CG. Muroyama Y, et al. Among authors: nirschl tr. Cancer Immunol Res. 2017 Nov;5(11):992-1004. doi: 10.1158/2326-6066.CIR-17-0040. Epub 2017 Oct 2. Cancer Immunol Res. 2017. PMID: 28970196 Free PMC article.
T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer.
Obradovic AZ, Dallos MC, Zahurak ML, Partin AW, Schaeffer EM, Ross AE, Allaf ME, Nirschl TR, Liu D, Chapman CG, O'Neal T, Cao H, Durham JN, Guner G, Baena-Del Valle JA, Ertunc O, De Marzo AM, Antonarakis ES, Drake CG. Obradovic AZ, et al. Among authors: nirschl tr. Clin Cancer Res. 2020 Jul 1;26(13):3182-3192. doi: 10.1158/1078-0432.CCR-19-3372. Epub 2020 Mar 15. Clin Cancer Res. 2020. PMID: 32173650 Free PMC article.
PD-L1 expression in medulloblastoma: an evaluation by subgroup.
Martin AM, Nirschl CJ, Polanczyk MJ, Bell WR, Nirschl TR, Harris-Bookman S, Phallen J, Hicks J, Martinez D, Ogurtsova A, Xu H, Sullivan LM, Meeker AK, Raabe EH, Cohen KJ, Eberhart CG, Burger PC, Santi M, Taube JM, Pardoll DM, Drake CG, Lim M. Martin AM, et al. Among authors: nirschl tr. Oncotarget. 2018 Apr 10;9(27):19177-19191. doi: 10.18632/oncotarget.24951. eCollection 2018 Apr 10. Oncotarget. 2018. PMID: 29721192 Free PMC article.
High-dimensional Cytometry (ExCYT) and Mass Spectrometry of Myeloid Infiltrate in Clinically Localized Clear Cell Renal Cell Carcinoma Identifies Novel Potential Myeloid Targets for Immunotherapy.
Theodros D, Murter BM, Sidhom JW, Nirschl TR, Clark DJ, Chen L, Tam AJ, Blosser RL, Schwen ZR, Johnson MH, Pierorazio PM, Zhang H, Ganguly S, Pardoll DM, Zarif JC. Theodros D, et al. Among authors: nirschl tr. Mol Cell Proteomics. 2020 Nov;19(11):1850-1859. doi: 10.1074/mcp.RA120.002049. Epub 2020 Jul 31. Mol Cell Proteomics. 2020. PMID: 32737216 Free PMC article.
Combined Next-generation Sequencing and Flow Cytometry Analysis for an Anti-PD-L1 Partial Responder over Time: An Exploration of Mechanisms of PD-L1 Activity and Resistance in Bladder Cancer.
Kates M, Nirschl TR, Baras AS, Sopko NA, Hahn NM, Su X, Zhang J, Kochel CM, Choi W, McConkey DJ, Drake CG, Bivalacqua TJ. Kates M, et al. Among authors: nirschl tr. Eur Urol Oncol. 2021 Feb;4(1):117-120. doi: 10.1016/j.euo.2019.01.017. Epub 2019 Feb 26. Eur Urol Oncol. 2021. PMID: 31411999
22 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page